A recent overview from Osmind highlights emerging evidence on GLP-1 receptor agonists (e.g., Ozempic, Wegovy) and their potential relevance in psychiatry and behavioral health.

Key Takeaways:

• Reduced substance use & cravings:Early studies suggest GLP-1 medications may reduce cravings for alcohol, nicotine, and possibly other substances—raising interest in their role for SUD treatment.

• Mental health effects (mixed but promising):Some patients report improvements in mood and compulsive behaviors, though data is still limited and not yet conclusive.

• Mechanism matters:These medications act on brain reward pathways (dopamine-related systems), which may explain effects on addiction and impulse control—not just appetite.

• Caution + monitoring needed:There are also reports of potential psychiatric side effects (e.g., mood changes, suicidal ideation), so careful screening and monitoring are essential.

• Not a standalone treatment:GLP-1s are not a replacement for behavioral health treatment but may become a complementary tool alongside therapy and recovery supports.

Why this matters for providers:

• Growing off-label interest among patients

• Potential future integration into SUD treatment models

• Need for clinical awareness, coordination, and ethical prescribing practice

See article here: https://www.osmind.org/blog/glp-1-psychiatry